MX2016014692A - Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos. - Google Patents

Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos.

Info

Publication number
MX2016014692A
MX2016014692A MX2016014692A MX2016014692A MX2016014692A MX 2016014692 A MX2016014692 A MX 2016014692A MX 2016014692 A MX2016014692 A MX 2016014692A MX 2016014692 A MX2016014692 A MX 2016014692A MX 2016014692 A MX2016014692 A MX 2016014692A
Authority
MX
Mexico
Prior art keywords
producing same
crystalline polymorph
pyridine derivative
novel crystalline
producing
Prior art date
Application number
MX2016014692A
Other languages
English (en)
Inventor
MOYAMOTO Hidetoshi
Nozato Hisae
Maruyama Akinobu
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2016014692A publication Critical patent/MX2016014692A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se describen cristales de ácido 2-(5-cloropiridin-3-il)-1-(2, 5-diclorobencil)-4-metil-1H-imidazol-5-carboxílico útiles como agentes terapéuticos o profilácticos para la gota, hiperuricemia, Y similares, y un método para producir los cristales.
MX2016014692A 2014-05-13 2015-05-12 Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos. MX2016014692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014099678 2014-05-13
PCT/JP2015/063632 WO2015174411A1 (ja) 2014-05-13 2015-05-12 ピリジン誘導体の新規な結晶多形体およびその製造方法

Publications (1)

Publication Number Publication Date
MX2016014692A true MX2016014692A (es) 2017-02-23

Family

ID=54479948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014692A MX2016014692A (es) 2014-05-13 2015-05-12 Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos.

Country Status (15)

Country Link
US (1) US20170144987A1 (es)
EP (1) EP3144304A4 (es)
JP (1) JP6289619B2 (es)
KR (1) KR20170003569A (es)
CN (1) CN106458970B (es)
AR (1) AR100404A1 (es)
AU (1) AU2015260294A1 (es)
CA (1) CA2948792A1 (es)
IL (1) IL248901A0 (es)
MX (1) MX2016014692A (es)
PH (1) PH12016502222A1 (es)
RU (1) RU2016148736A (es)
SG (1) SG11201609483YA (es)
TW (1) TW201625580A (es)
WO (1) WO2015174411A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000051I1 (de) * 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
WO2007148787A1 (ja) * 2006-06-23 2007-12-27 Teijin Pharma Limited ２－（３－シアノ－４－イソブチルオキシフェニル）－４－メチル－５－チアゾールカルボン酸の結晶多形体の製造方法
JP5314123B2 (ja) * 2008-03-31 2013-10-16 シー アンド シー リサーチ ラボラトリーズ 複素環誘導体
PL2404908T3 (pl) * 2009-02-27 2014-12-31 Teijin Ltd Sposób wytwarzania podstawionej fenylem pochodnej heterocyklicznej przez sprzężenie z użyciem katalizatora metalu przejściowego
TWI516480B (zh) * 2009-07-15 2016-01-11 Teijin Pharma Ltd A method for producing a crystalline polymorph of 2- (3-cyano-4-isobutyloxyphenyl) -4-methyl-5-thiazolecarboxylic acid by a poor solvent addition method
JP5519201B2 (ja) * 2009-07-15 2014-06-11 光孝 北村 ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
SG187843A1 (en) * 2010-08-27 2013-03-28 Teijin Pharma Ltd Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound
NZ708031A (en) * 2012-11-14 2018-04-27 Teijin Pharma Ltd Pyridine derivative

Also Published As

Publication number Publication date
JP6289619B2 (ja) 2018-03-07
TW201625580A (zh) 2016-07-16
IL248901A0 (en) 2017-01-31
SG11201609483YA (en) 2016-12-29
JPWO2015174411A1 (ja) 2017-04-20
US20170144987A1 (en) 2017-05-25
AR100404A1 (es) 2016-10-05
PH12016502222A1 (en) 2017-02-06
AU2015260294A1 (en) 2017-01-05
EP3144304A1 (en) 2017-03-22
CN106458970A (zh) 2017-02-22
WO2015174411A1 (ja) 2015-11-19
KR20170003569A (ko) 2017-01-09
RU2016148736A (ru) 2018-06-14
RU2016148736A3 (es) 2018-06-14
EP3144304A4 (en) 2017-10-25
CN106458970B (zh) 2019-09-13
CA2948792A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
PH12016501941B1 (en) Use of heterocyclic compounds for controlling nematodes
IL266214B (en) 5,4,2-tri-converted 4,2,1-triazolones used as dhodh inhibitors
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
HK1246286A1 (zh) Lrrk2抑制剂及其制备和使用方法
EP3164130A4 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JO3722B1 (ar) مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات
HK1253372A1 (zh) 作为bace1抑制剂的2-氨基-3-氟-3-(氟甲基)-6-甲基-6-苯基-3，4，5，6-四氢吡啶
MX2019007629A (es) Proceso para la preparacion de un derivado de 2-piridiletilcarboxamida.
WO2015142903A3 (en) Method of controlling lactate production with piperdine-dione derivatives
HK1223367A1 (zh) 新型dgat2抑制劑
MX2019006715A (es) Metodo de preparacion de compuestos triciclicos.
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX2017015662A (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
MX385672B (es) Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida.
ZA202000381B (en) Process for making esters of 2,5-furandicarboxylic acid
EP3118207A4 (en) Inclusion compound of 3',5'-cyclicdiadenylic acid, and method for producing same
WO2015102024A3 (en) Novel substituted 5 membered heterocyclic compounds and preparation thereof
MX2016014692A (es) Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos.
WO2015104602A3 (en) A process for the preparation of anagliptin and its intermediates thereof
MX2017000412A (es) Derivado de azol-benceno y forma cristalina del mismo.
HK40036207A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
AU2014378009A1 (en) Synthesis method of 9-allylcamptothecin derivatives
HK1199024A1 (zh) 可作為mogat-2抑制物使用之新型嗎啉基衍生物